WO2005079770A8 - Utilisation d'un compose modulateur d'au moins un recepteur choisi parmi le recepteur de type b de l'il 8 et de type 1 de pacap pour la preparation d'une composition pharmaceutique pour traiter la rosacee - Google Patents

Utilisation d'un compose modulateur d'au moins un recepteur choisi parmi le recepteur de type b de l'il 8 et de type 1 de pacap pour la preparation d'une composition pharmaceutique pour traiter la rosacee

Info

Publication number
WO2005079770A8
WO2005079770A8 PCT/FR2005/000366 FR2005000366W WO2005079770A8 WO 2005079770 A8 WO2005079770 A8 WO 2005079770A8 FR 2005000366 W FR2005000366 W FR 2005000366W WO 2005079770 A8 WO2005079770 A8 WO 2005079770A8
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
pacap
interleukin
preparing
pharmaceutical composition
Prior art date
Application number
PCT/FR2005/000366
Other languages
English (en)
Other versions
WO2005079770A2 (fr
Inventor
Fabrizio Dolfi
Irina Safonova
Original Assignee
Galderma Res & Dev
Fabrizio Dolfi
Irina Safonova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev, Fabrizio Dolfi, Irina Safonova filed Critical Galderma Res & Dev
Priority to EP05729353A priority Critical patent/EP1718285A2/fr
Priority to US10/589,991 priority patent/US20080033060A1/en
Priority to CA002553188A priority patent/CA2553188A1/fr
Publication of WO2005079770A2 publication Critical patent/WO2005079770A2/fr
Publication of WO2005079770A8 publication Critical patent/WO2005079770A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/FR2005/000366 2004-02-20 2005-02-17 Utilisation d'un compose modulateur d'au moins un recepteur choisi parmi le recepteur de type b de l'il 8 et de type 1 de pacap pour la preparation d'une composition pharmaceutique pour traiter la rosacee WO2005079770A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05729353A EP1718285A2 (fr) 2004-02-20 2005-02-17 Utilisation d'un compose modulateur d'au moins un recepteur choisi parmi le recepteur de type b de l'il 8 et de type 1 de pacap pour la preparation d'une composition pharmaceutique pour traiter la rosacee
US10/589,991 US20080033060A1 (en) 2004-02-20 2005-02-17 Use Of A Compound Modulating At Least One Receiver Selected In A Group Comprising An Interleukin 8 Type B Receptor And Pacap-1 Receptor For Porparing A Pharmaceutical Composition For Rosacea Treatment
CA002553188A CA2553188A1 (fr) 2004-02-20 2005-02-17 Utilisation d'un compose modulateur d'au moins un recepteur choisi parmi le recepteur de type b de l'il 8 et de type 1 de pacap pour la preparation d'une composition pharmaceutique pour traiter la rosacee

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0401716A FR2866565A1 (fr) 2004-02-20 2004-02-20 Utilisation d'un modulateur du il-8rb et/ou pac-1 pour le traitement de la rosacee
FR0401716 2004-02-20

Publications (2)

Publication Number Publication Date
WO2005079770A2 WO2005079770A2 (fr) 2005-09-01
WO2005079770A8 true WO2005079770A8 (fr) 2005-10-27

Family

ID=34833941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/000366 WO2005079770A2 (fr) 2004-02-20 2005-02-17 Utilisation d'un compose modulateur d'au moins un recepteur choisi parmi le recepteur de type b de l'il 8 et de type 1 de pacap pour la preparation d'une composition pharmaceutique pour traiter la rosacee

Country Status (5)

Country Link
US (1) US20080033060A1 (fr)
EP (1) EP1718285A2 (fr)
CA (1) CA2553188A1 (fr)
FR (1) FR2866565A1 (fr)
WO (1) WO2005079770A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010007175A2 (fr) * 2008-07-18 2010-01-21 Galderma Research & Development Modulateurs de voie de signalisation pacap pour traiter des maladies inflammatoires de la peau avec une composante neurogène et plus particulièrement l’acné rosacée et composition contenant ceux-ci
FR2961695B1 (fr) * 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes

Also Published As

Publication number Publication date
US20080033060A1 (en) 2008-02-07
WO2005079770A2 (fr) 2005-09-01
CA2553188A1 (fr) 2005-09-01
FR2866565A1 (fr) 2005-08-26
EP1718285A2 (fr) 2006-11-08

Similar Documents

Publication Publication Date Title
AU2003266133A1 (en) Materials and methods for drug delivery and uptake
AU2003278393A1 (en) New use for pharmaceutical composition
IL164376A0 (en) Ox4or binding agents, their preparation and pharmaceutical compositions containing them
AU2003286639A1 (en) Mixing and delivery medical syringe system for therapeutic compositions
AU2003291103A1 (en) Pharmaceutical composition
AU2003268087A1 (en) Liposomal gemcitabine compositions for better drug delivery
HK1123789A1 (en) Azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same
IL162765A (en) Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
EP1691864B8 (fr) Systeme d'administration de tampons
AU2003250372A1 (en) Pharmaceutical composition
AU2003255645A1 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
AU2003231352A1 (en) Biocidal formulation and methods for the preparation thereof
EP1670894B8 (fr) Compositions comprenant divers types de facteur de transfert, procedes de preparation des compositions et methodes de traitement mettant en oeuvre les compositions
WO2005079770A8 (fr) Utilisation d'un compose modulateur d'au moins un recepteur choisi parmi le recepteur de type b de l'il 8 et de type 1 de pacap pour la preparation d'une composition pharmaceutique pour traiter la rosacee
AU2003272127A1 (en) Polymeric composition for drug delivery
AU2003226746A1 (en) Intravaginal matrix drug delivery devices
EP1711490A4 (fr) Inhibiteur de p-glycoproteine, procede de preparation, et composition pharmaceutique le renfermant
AU2002308649A1 (en) Compositions and methods for enhancing drug delivery
AU2003284460A1 (en) Medicinal composition
HK1107256A1 (en) Compositions containing nicorandil, preparation method and use
AU2003280799A1 (en) Medicinal composition
AU2003260566A1 (en) Phenyl-furan or phenyl-thiophene derivatives, their preparation and their use as medicine
AU2003297589A1 (en) Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
AU2003228305A1 (en) Pharmaceutical composition with combined active agents and methods for using the same
AU2003283508A1 (en) .pharmaceutical composition comprising htless thansbgreater than4less than/sbgreater thandless thanspgreater than100less than/spgreater thana receptors, and therapeutic uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

D17 Declaration under article 17(2)a
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005729353

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2553188

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005729353

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10589991

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10589991

Country of ref document: US